You’re not going to believe what they slipped into the Federal Register last Tuesday, buried between notices about fish imports and agricultural tariffs.
It’s the kind of thing that makes you wonder if the entire war on cancer has been fought with the wrong weapons on purpose. I’m not saying there’s a cure being hidden in a vault somewhere—that’s too simple, too Hollywood. But what I am saying is that the data trail, the breadcrumbs left in clinical trial documents and profit statements, leads to a conclusion that will shake your faith in the white coats.
We’ve been told for decades to trust the process. “Science is on our side.” “We’re winning the war.” But when you actually pull back the curtain on the FDA’s own accelerated approval pathway, you start to see the mechanism isn’t designed to cure you. It’s designed to manage you. And that’s a very different business model.
Let’s talk about the “Disease Mongering” that starts at the cellular level.
We all know someone. A cousin, a father, a best friend. They get the diagnosis, and suddenly the world stops. The oncologist, usually a well-meaning guy who drives a nice car, immediately puts them on a regimen of chemotherapy or the latest “miracle” immunotherapy drug—often costing upwards of $100,000 a year.
But here’s the dot that nobody in the mainstream media wants you to connect: The FDA has admitted, in black and white, that a significant portion of these cancer drugs are approved based on **surrogate endpoints**. Not survival. Not a cure. They’re approving drugs that shrink tumors on a scan for a few months, even if that shrinkage does absolutely nothing to extend the patient's actual life.
It’s called the “PFS” game—Progression-Free Survival. It’s a metric that makes the drug look effective on paper, but in real-world terms, it often just means you live with the side effects of the poison while the clock ticks on the same timeline.
Why? Because shrinking a tumor for four extra months is easier to prove in a trial than keeping someone alive for five years. And getting a drug to market faster means the patent clock starts ticking sooner. It’s a race to the bank, not a race to the cure.
Look at the data from a 2023 analysis published in the *BMJ*. They looked at 39 cancer drugs approved via the FDA’s expedited pathways. The result? For most of these drugs, there was **zero evidence** that they improved overall survival or quality of life. Zero. Yet, they are the standard of care.
You have to ask yourself: If the treatment doesn’t extend life, and it costs six figures a year, who is the real patient? The human, or the portfolio?
Now, let’s take this one step deeper into the rabbit hole—the genetic component.
The grand narrative is that cancer is a random mutation. A roll of the dice. But as we map the human genome, we are finding that many cancers are not random at all. They are environmental. They are dietary. They are inflammatory. They are the result of a body that is being constantly assaulted by the chemical soup we live in—from the PFAS in our water to the glyphosate on our wheat to the endocrine disruptors in our receipts.
But notice how the funding flows. The National Cancer Institute gives billions to find the one rogue gene, the "target." They are looking for the bullet, not the gun. If they admitted that the cause is the environment, then the solution isn't a patented pill—it’s regulation. It’s cleaning up the water supply. It’s banning the toxins. And you can't put a patent on clean water.
That’s the "stay woke" moment. The system is structured to treat the symptom (the tumor) rather than the cause (the toxic load). Because treating the symptom is infinitely profitable.
And what about the "cures" that already exist in plain sight?
I’m not talking about apricot seeds or essential oils—that’s the other side of the disinformation coin designed to make you look crazy. I’m talking about metabolic therapy. I’m talking about the role of glucose and the ketogenic diet in starving cancer cells, something Dr. Thomas Seyfried has been shouting from the rooftops for years. His research shows that cancer is primarily a metabolic disease, not a genetic one.
If cancer cells are primarily fueled by glucose and glutamine, why isn't metabolic intervention the first line of defense? Why is it always the slash, burn, and poison approach?
Because chemotherapy is a multi-billion dollar industry. Radiation therapy requires billion-dollar machines that need to be amortized. The entire infrastructure of a modern hospital is built on the "cut-burn-poison" model. To pivot to a dietary and metabolic approach would require dismantling the entire system. It would bankrupt the very institutions we are told to trust.
The FDA knows this. They admitted that they don't require proof of long-term survival for many approvals. They just require proof that the drug does *something* to the tumor.
So the next time you hear about a "breakthrough," read the fine print. Look for the word "surrogate." Look for the PFS data. And if they don't show you the Overall Survival curve, ask why.
We are waking up to the reality that the medical-industrial complex is a profit machine first and a healing institution second. The admission is right there in the data. The dots are there to connect. The question is: are you brave enough to look at them, or are you going to keep trusting the man behind the curtain?
Final Thoughts
Having spent decades covering medical breakthroughs, I've learned that the word "cancer" is less a single verdict and more a sprawling, mutable landscape—one where a patient's zip code, genetics, and even the timing of diagnosis can matter as much as the pathology report. The real story isn't just in the lab's latest targeted therapy, but in the brutal arithmetic of access: we’ve made staggering progress against the disease itself, yet we remain painfully inept at curing the systemic inequities that determine who gets to benefit from it. Ultimately, this fight is a mirror held up to our society, and the most honest conclusion is that we haven't just lost patients to cancer—we've lost too many to the silence between scans, the delays in care, and the cost of hope.